354390.Kn
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with a current ratio of 6.87, indicating a significant buffer of current assets over current liabilities. It also holds substantial cash and equivalents of KRW 3,535,412,920, which supports its operational flexibility and financial stability. The company's free cash flow of KRW 5,941,628,730 further reinforces its ability to fund operations, invest in growth, and return value to shareholders.
In terms of profitability, the company demonstrates a return on equity (ROE) of 13.19% and a return on assets (ROA) of 11.63%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets. The operating margin, calculated as operating income of KRW 2,894,178,640 on revenue of KRW 33,520,492,950, is approximately 8.63%, which is a key performance indicator for the pharmaceutical industry.
The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic breakdown provided in the available data. This suggests that the company's operations are not diversified across multiple geographic regions, which could expose it to regional economic or regulatory risks.
The company's growth trajectory is supported by its strong free cash flow and operating cash flow of KRW 5,941,628,730 and KRW 4,088,180,260, respectively. These figures indicate a capacity for reinvestment and expansion. However, the capital expenditure of KRW -726,246,000 suggests that the company is not currently investing heavily in new infrastructure or facilities.
The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.0, meaning it is not currently leveraging debt to finance its operations, which reduces financial risk. However, the absence of debt could also limit the company's ability to capitalize on growth opportunities.
There are no recent events or filings disclosed in the available data that would suggest material changes in the company's operations or financial position. The company appears to be operating in a stable environment with no immediate regulatory or market disruptions.
- The company has a strong liquidity position with a current ratio of 6.87 and substantial cash reserves.
- It generates solid returns with a ROE of 13.19% and ROA of 11.63%.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Free cash flow and operating cash flow are robust, supporting reinvestment and shareholder returns.
- The company is not currently using debt to finance operations, which reduces financial risk but may limit growth opportunities.
- No immediate liquidity or dilution risks are identified in the available data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 354390.KN Market data — financials · 2026-05-26